Combining tau-PET and fMRI meta-analyses for patient-centered prediction of cognitive decline in Alzheimer's disease.
Humans
Aged
Aged, 80 and over
Alzheimer Disease
/ diagnosis
Magnetic Resonance Imaging
/ methods
tau Proteins
/ metabolism
Positron-Emission Tomography
/ methods
Cognitive Dysfunction
/ diagnostic imaging
Brain
/ diagnostic imaging
Amyloid
/ metabolism
Patient-Centered Care
Amyloid beta-Peptides
/ metabolism
Alzheimer’s disease
Cognitive decline
Precision medicine
Tau-PET
fMRI
Journal
Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643
Informations de publication
Date de publication:
07 11 2022
07 11 2022
Historique:
received:
20
06
2022
accepted:
20
10
2022
entrez:
8
11
2022
pubmed:
9
11
2022
medline:
10
11
2022
Statut:
epublish
Résumé
Tau-PET is a prognostic marker for cognitive decline in Alzheimer's disease, and the heterogeneity of tau-PET patterns matches cognitive symptom heterogeneity. Thus, tau-PET may allow precision-medicine prediction of individual tau-related cognitive trajectories, which can be important for determining patient-specific cognitive endpoints in clinical trials. Here, we aimed to examine whether tau-PET in cognitive-domain-specific brain regions, identified via fMRI meta-analyses, allows the prediction of domain-specific cognitive decline. Further, we aimed to determine whether tau-PET-informed personalized cognitive composites capture patient-specific cognitive trajectories more sensitively than conventional cognitive measures. We included Alzheimer's Disease Neuroimaging Initiative (ADNI) participants classified as controls (i.e., amyloid-negative, cognitively normal, n = 121) or Alzheimer's disease-spectrum (i.e., amyloid-positive, cognitively normal to dementia, n = 140), plus 111 AVID-1451-A05 participants for independent validation (controls/Alzheimer's disease-spectrum=46/65). All participants underwent baseline In both amyloid-positive cohorts (ADNI [age = 75.99±7.69] and A05 [age = 74.03±9.03]), cognitive-domain-specific tau-PET outperformed global and temporal-lobe tau-PET for predicting future cognitive decline in episodic memory, language, executive functioning, and visuospatial abilities. Further, a tau-PET-informed personalized cognitive composite across cognitive domains enhanced the sensitivity to assess cognitive decline in amyloid-positive subjects, yielding lower sample sizes required for detecting simulated intervention effects compared to conventional cognitive endpoints (i.e., memory composite, global cognitive composite). However, the latter effect was less strong in A05 compared to the ADNI cohort. Combining tau-PET with task-fMRI-derived maps of major cognitive domains facilitates the prediction of domain-specific cognitive decline. This approach may help to increase the sensitivity to detect Alzheimer's disease-related cognitive decline and to determine personalized cognitive endpoints in clinical trials.
Sections du résumé
BACKGROUND
Tau-PET is a prognostic marker for cognitive decline in Alzheimer's disease, and the heterogeneity of tau-PET patterns matches cognitive symptom heterogeneity. Thus, tau-PET may allow precision-medicine prediction of individual tau-related cognitive trajectories, which can be important for determining patient-specific cognitive endpoints in clinical trials. Here, we aimed to examine whether tau-PET in cognitive-domain-specific brain regions, identified via fMRI meta-analyses, allows the prediction of domain-specific cognitive decline. Further, we aimed to determine whether tau-PET-informed personalized cognitive composites capture patient-specific cognitive trajectories more sensitively than conventional cognitive measures.
METHODS
We included Alzheimer's Disease Neuroimaging Initiative (ADNI) participants classified as controls (i.e., amyloid-negative, cognitively normal, n = 121) or Alzheimer's disease-spectrum (i.e., amyloid-positive, cognitively normal to dementia, n = 140), plus 111 AVID-1451-A05 participants for independent validation (controls/Alzheimer's disease-spectrum=46/65). All participants underwent baseline
RESULTS
In both amyloid-positive cohorts (ADNI [age = 75.99±7.69] and A05 [age = 74.03±9.03]), cognitive-domain-specific tau-PET outperformed global and temporal-lobe tau-PET for predicting future cognitive decline in episodic memory, language, executive functioning, and visuospatial abilities. Further, a tau-PET-informed personalized cognitive composite across cognitive domains enhanced the sensitivity to assess cognitive decline in amyloid-positive subjects, yielding lower sample sizes required for detecting simulated intervention effects compared to conventional cognitive endpoints (i.e., memory composite, global cognitive composite). However, the latter effect was less strong in A05 compared to the ADNI cohort.
CONCLUSION
Combining tau-PET with task-fMRI-derived maps of major cognitive domains facilitates the prediction of domain-specific cognitive decline. This approach may help to increase the sensitivity to detect Alzheimer's disease-related cognitive decline and to determine personalized cognitive endpoints in clinical trials.
Identifiants
pubmed: 36345046
doi: 10.1186/s13195-022-01105-5
pii: 10.1186/s13195-022-01105-5
pmc: PMC9639286
doi:
Substances chimiques
tau Proteins
0
Amyloid
0
Amyloid beta-Peptides
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
166Informations de copyright
© 2022. The Author(s).
Références
Brain. 2020 Apr 1;143(4):1249-1260
pubmed: 32176777
Acta Neuropathol. 1991;82(4):239-59
pubmed: 1759558
Alzheimers Dement (N Y). 2019 May 20;5:164-174
pubmed: 31193334
J Alzheimers Dis. 2021;80(3):1091-1104
pubmed: 33682705
Neurology. 2021 Jun 1;96(22):e2673-e2684
pubmed: 34550903
Neuron. 2016 Mar 2;89(5):971-982
pubmed: 26938442
J Neurosci. 2011 Nov 2;31(44):15775-86
pubmed: 22049421
Brain. 2018 May 1;141(5):1486-1500
pubmed: 29522171
JAMA Neurol. 2021 Aug 1;78(8):961-971
pubmed: 34180956
Cold Spring Harb Perspect Med. 2012 Apr;2(4):a006171
pubmed: 22474609
Alzheimers Dement. 2014 Nov;10(6):666-74
pubmed: 24751827
Alzheimers Dement. 2011 May;7(3):263-9
pubmed: 21514250
Nat Med. 2021 Jul;27(7):1187-1196
pubmed: 34155411
JAMA Neurol. 2015 Mar;72(3):316-24
pubmed: 25580592
Arch Neurol. 2007 Sep;64(9):1323-9
pubmed: 17846273
Alzheimers Dement. 2018 Apr;14(4):535-562
pubmed: 29653606
EMBO Mol Med. 2020 Sep 7;12(9):e12308
pubmed: 32790063
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
Brain. 2019 Jun 1;142(6):1723-1735
pubmed: 31009046
Mol Psychiatry. 2021 Oct;26(10):5888-5898
pubmed: 34593971
Alzheimers Dement. 2011 May;7(3):270-9
pubmed: 21514249
Lancet Neurol. 2021 Jun;20(6):484-496
pubmed: 33933186
Alzheimers Res Ther. 2018 Dec 19;10(1):122
pubmed: 30567585
Lancet Neurol. 2007 Aug;6(8):734-46
pubmed: 17616482
Brain. 2017 Dec 1;140(12):3286-3300
pubmed: 29053874
PLoS Comput Biol. 2017 Oct 23;13(10):e1005649
pubmed: 29059185
Brain. 2018 May 1;141(5):1517-1528
pubmed: 29538647
Brain Imaging Behav. 2012 Dec;6(4):502-16
pubmed: 22782295
Crit Care. 2016 Aug 03;20(1):218
pubmed: 27485596
JAMA Netw Open. 2020 Mar 2;3(3):e200413
pubmed: 32142126
Alzheimers Dement (Amst). 2018 Feb 23;10:232-236
pubmed: 29780868
Sci Adv. 2020 Nov 27;6(48):
pubmed: 33246962
Lancet Neurol. 2014 Jun;13(6):614-29
pubmed: 24849862
Brain. 2021 Oct 22;144(9):2771-2783
pubmed: 33725124
Curr Opin Neurobiol. 2011 Dec;21(6):929-34
pubmed: 22079495
Alzheimers Res Ther. 2021 Apr 17;13(1):80
pubmed: 33865446
JAMA Neurol. 2021 Apr 1;78(4):445-453
pubmed: 33587110
PLoS Comput Biol. 2011 Nov;7(11):e1002251
pubmed: 22072952
J Neurosci. 2017 Apr 19;37(16):4323-4331
pubmed: 28314821
Nat Neurosci. 2019 Jan;22(1):57-64
pubmed: 30559471
Neurobiol Aging. 2020 Aug;92:141-152
pubmed: 32280029
Alzheimers Res Ther. 2021 Aug 12;13(1):137
pubmed: 34384484
Alzheimers Dement (N Y). 2020 Dec 05;6(1):e12072
pubmed: 33313380
Brain. 2016 May;139(Pt 5):1551-67
pubmed: 26962052
Mol Psychiatry. 2019 Aug;24(8):1112-1134
pubmed: 30635637
Nat Commun. 2020 May 26;11(1):2612
pubmed: 32457389
Alzheimers Res Ther. 2018 Sep 11;10(1):90
pubmed: 30205840
Cereb Cortex. 2014 Jun;24(6):1422-35
pubmed: 23314940
Nat Med. 2021 May;27(5):871-881
pubmed: 33927414
Nat Methods. 2011 Jun 26;8(8):665-70
pubmed: 21706013